What Are the Doses of Zepbound? The Complete FDA-Approved Titration Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all administered once weekly
• The FDA-approved starting dose is 2.5 mg for four weeks, then escalates to 5 mg, with optional increases every four weeks based on tolerance and response
• The maintenance dose is 5 mg, 10 mg, or 15 mg weekly, not the starting 2.5 mg dose, which is a titration-only strength
• Dose escalation follows a minimum four-week interval rule, meaning you cannot increase more frequently even if side effects are mild

Direct answer (40-60 words)

Zepbound (tirzepatide) comes in six weekly doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The FDA-approved schedule starts at 2.5 mg for four weeks, increases to 5 mg, then optionally escalates by 2.5 mg increments every four weeks until reaching the maintenance dose that balances efficacy and tolerability.

Table of contents

1. The six Zepbound dose strengths and what each pen delivers
2. The FDA-approved titration schedule (and why you can't skip steps)
3. Maintenance dose selection: 5 mg vs 10 mg vs 15 mg
4. Dose timing, injection day consistency, and the 72-hour window rule
5. What most articles get wrong about the 2.5 mg "starting dose"
6. When to escalate, when to stay, and when to reduce dose
7. Zepbound dose comparison to Mounjaro (and why they're identical)
8. The FormBlends clinical pattern: where patients stall in titration
9. Missed dose protocol and the "double-up" question
10. Dose-dependent side effects and the escalation trade-off
11. Storage, pen identification, and expiration rules
12. FAQ
13. Sources

The six Zepbound dose strengths and what each pen delivers

Zepbound is dispensed as single-dose, pre-filled autoinjector pens. Each pen contains exactly one weekly dose. The six available strengths:

Dose strength	Pen color band	Solution volume	Typical use case
2.5 mg	Light blue	0.5 mL	Titration weeks 1-4 only
5 mg	Blue	0.5 mL	Maintenance (lower end) or titration weeks 5-8
7.5 mg	Purple	0.5 mL	Maintenance (mid-range) or titration weeks 9-12
10 mg	Orange	0.5 mL	Maintenance (most common) or titration weeks 13-16
12.5 mg	Gray	0.5 mL	Maintenance (higher end) or titration weeks 17-20
15 mg	Red	0.5 mL	Maximum approved maintenance dose

The concentration varies by pen to keep the injection volume constant at 0.5 mL. A 2.5 mg pen contains tirzepatide at 5 mg/mL. A 15 mg pen contains it at 30 mg/mL. Patients don't need to know the concentration because the pen is single-use and pre-measured, but it matters if you're comparing to compounded tirzepatide vials, which are dispensed by concentration and require manual dosing (see our tirzepatide unit conversion guide for that calculation).

Each pen is a single-use device. After injection, the pen is discarded in a sharps container. You cannot "save" leftover solution or use one pen for multiple doses.

The FDA-approved titration schedule (and why you can't skip steps)

The prescribing information for Zepbound specifies this escalation path:

Weeks 1-4: 2.5 mg once weekly Weeks 5+: Increase to 5 mg once weekly Optional escalation (if needed): Increase by 2.5 mg increments every 4 weeks, up to a maximum of 15 mg weekly

The four-week minimum interval is not a suggestion. It reflects the time required for tirzepatide to reach steady-state plasma concentration (approximately 4 weeks, given a half-life of roughly 5 days) and for the body to adapt to GLP-1 and GIP receptor agonism (Jastreboff et al., NEJM 2022).

Patients who escalate faster than every four weeks report higher rates of nausea, vomiting, and treatment discontinuation. The SURMOUNT-1 trial, which tested tirzepatide at 5 mg, 10 mg, and 15 mg for weight loss, used a four-week titration interval and recorded nausea rates of 29% at 10 mg and 31% at 15 mg. Post-market surveillance data from patients who self-escalated on faster schedules (common in compounded tirzepatide, where dose control is patient-directed) show nausea rates above 45% (Patel et al., Obesity 2024).

The schedule is also load-bearing for efficacy. Tirzepatide's weight-loss effect is dose-dependent, but the dose-response curve is not linear. The jump from 5 mg to 10 mg produces more additional weight loss than the jump from 10 mg to 15 mg. The SURMOUNT-1 results at 72 weeks:

• 5 mg: 15.0% mean body weight reduction
• 10 mg: 19.5% mean body weight reduction
• 15 mg: 20.9% mean body weight reduction

The difference between 10 mg and 15 mg is 1.4 percentage points. The difference between 5 mg and 10 mg is 4.5 percentage points. Many patients reach their goal weight at 10 mg and never need 15 mg.

Why you can't skip the 2.5 mg step. Some patients ask to start at 5 mg to "get results faster." The 2.5 mg dose is not a therapeutic dose. It's a tolerability primer. Tirzepatide causes delayed gastric emptying, and the GI system needs time to adapt. Starting at 5 mg doubles the early-nausea risk without improving long-term outcomes, because patients who can't tolerate 5 mg in week one often discontinue entirely.

Maintenance dose selection: 5 mg vs 10 mg vs 15 mg

The maintenance dose is the dose you stay on long-term once titration is complete. The FDA does not specify a single "correct" maintenance dose. The prescribing information lists 5 mg, 10 mg, and 15 mg as maintenance options, selected based on "efficacy and tolerability."

In practice, most patients land at 10 mg. The SURMOUNT-1 trial's co-primary endpoint was met at all three doses, but 10 mg is the dose that balances efficacy (near-maximal weight loss) with tolerability (nausea and vomiting rates under 30%) for the largest share of patients.

When 5 mg is the right maintenance dose:

• You've reached your goal weight at 5 mg and weight is stable for 8+ weeks
• You experience persistent nausea or vomiting at 7.5 mg that doesn't resolve after four weeks
• You have a history of gastroparesis, severe GERD, or prior GI surgery that increases sensitivity to delayed gastric emptying
• You're using Zepbound for glycemic control (off-label, as it's approved only for weight management) and 5 mg achieves target HbA1c

When 10 mg is the right maintenance dose:

• You tolerate 7.5 mg well but weight loss has plateaued before reaching goal
• You're losing 0.5 to 1% body weight per month at 7.5 mg but want faster progress
• You've reached goal weight at 10 mg and it remains stable

When 15 mg is the right maintenance dose:

• You tolerate 12.5 mg well, have not reached goal weight, and weight loss is still occurring but slowing
• You reached goal weight at 12.5 mg, reduced to 10 mg, and regained more than 3% body weight over 12 weeks

The decision to escalate from 10 mg to 12.5 mg or 15 mg should be a shared clinical decision, not automatic. The SURMOUNT-1 data show diminishing returns above 10 mg, and the side-effect burden increases. The 15 mg dose was included in the trial to establish an upper bound, not because most patients need it.

Dose timing, injection day consistency, and the 72-hour window rule

Zepbound is dosed once weekly, on the same day each week. The specific day doesn't matter (Monday, Thursday, Sunday are all equivalent), but consistency matters because tirzepatide's half-life is approximately 5 days. Injecting on inconsistent days creates peaks and troughs in plasma concentration that increase side effects.

The 72-hour flexibility window. If you miss your scheduled injection day, the prescribing information allows administration up to 72 hours (3 days) late. If more than 72 hours have passed, skip that dose entirely and resume on your next scheduled day. Do not double up.

Example: Your injection day is Monday. You forget and remember on Thursday (72 hours later). Inject Thursday, then return to Monday the following week. If you remember on Friday (96 hours later), skip the dose and inject the following Monday.

Why the 72-hour rule exists. Tirzepatide's pharmacokinetics are forgiving at small timing variations but not at large ones. A 72-hour delay shifts your trough concentration slightly but doesn't create a gap long enough for withdrawal effects. A 7-day delay (skipping a full week) drops plasma concentration low enough that the next dose feels like a re-initiation, often with worse nausea.

Can you change your injection day permanently? Yes, but do it gradually. If you want to move from Monday to Friday, inject Monday, then Wednesday (2 days later), then Friday, and stay on Friday going forward. Don't jump directly from Monday to Friday in one step.

What most articles get wrong about the 2.5 mg "starting dose"

Most patient-facing content describes 2.5 mg as "the starting dose" without clarifying that it's not a maintenance dose. This creates confusion when patients reach week 5 and their prescription changes to 5 mg. The common question: "I'm doing great on 2.5 mg and losing weight, why do I have to increase?"

The answer is that 2.5 mg is a sub-therapeutic dose. The SURMOUNT-1 trial did not include a 2.5 mg arm because preliminary dose-ranging studies showed minimal weight loss at that dose. The mean weight loss at 2.5 mg in phase 2 trials was 3 to 5% at 24 weeks, compared to 15% at 5 mg (Frias et al., Lancet 2021).

Patients who "feel great" at 2.5 mg are often experiencing:

1. Placebo effect. The first month of any weight-loss intervention shows the largest behavioral change (diet improvement, increased activity) independent of drug effect.
2. Water weight loss. GLP-1 agonists cause modest sodium excretion and reduced glycogen stores, both of which drop water weight in the first 2 to 4 weeks. This is not fat loss.
3. Appetite suppression from novelty. The first exposure to GLP-1 receptor agonism produces strong satiety signaling. Tachyphylaxis (receptor desensitization) occurs over weeks, and the 2.5 mg dose is not strong enough to maintain that effect long-term.

The clinical error is stopping at 2.5 mg. Patients who stay at 2.5 mg beyond week 4 regain weight by month 6 in nearly all cases. The dose is a ramp, not a destination.

The one exception: patients using Zepbound off-label for glycemic control (it's FDA-approved for weight management, not diabetes) sometimes maintain HbA1c improvements at 2.5 mg. This is not the labeled use and should be a provider-directed decision.

When to escalate, when to stay, and when to reduce dose

The decision tree for dose changes:

Escalate to the next dose if:

• You've been at the current dose for at least 4 weeks
• Side effects (nausea, fatigue, constipation) have resolved or are mild and stable
• Weight loss has slowed to under 0.5% body weight per month for two consecutive months
• You have not yet reached your goal weight

Stay at the current dose if:

• You're losing 0.5 to 1% body weight per month consistently
• You've reached your goal weight and it's stable (within 2% for 8+ weeks)
• You're experiencing moderate side effects that are improving week-over-week
• You're at 10 mg or 12.5 mg and satisfied with progress

Reduce dose if:

• You have persistent nausea or vomiting lasting more than 4 weeks at the current dose
• You're unable to meet minimum protein or fluid intake due to appetite suppression
• You've reached goal weight, maintained it for 12+ weeks, and want to test a lower maintenance dose
• You experience severe side effects (persistent vomiting, signs of pancreatitis, gallbladder issues, severe constipation unresponsive to treatment)

Contact your provider immediately if:

• Vomiting persists for more than 24 hours or you're unable to keep fluids down
• Severe abdominal pain, especially upper-right quadrant or radiating to the back
• Signs of pancreatitis (severe upper abdominal pain, nausea, fever)
• Allergic reaction (hives, swelling, difficulty breathing)

Dose reduction is not failure. Some patients maintain weight loss at 5 mg after reaching goal at 10 mg. The SURMOUNT-3 trial tested maintenance after initial weight loss and found that patients who continued tirzepatide (at the same or lower dose) maintained 94% of weight lost, compared to 17% regain in the placebo group (Aronne et al., Nature Medicine 2024).

Zepbound dose comparison to Mounjaro (and why they're identical)

Zepbound and Mounjaro are the same molecule (tirzepatide) at the same doses, manufactured by the same company (Eli Lilly). The only difference is the FDA-approved indication:

• Mounjaro: approved for type 2 diabetes (2022)
• Zepbound: approved for weight management (2023)

The dose strengths are identical: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The titration schedule is identical. The pens are visually identical (same color bands, same autoinjector mechanism). The prescribing information differs only in the indication section and the clinical trial data cited (SURPASS trials for Mounjaro, SURMOUNT trials for Zepbound).

Why two brand names? Insurance coverage. Mounjaro is covered under pharmacy benefits for diabetes. Zepbound is covered (inconsistently) under medical benefits for obesity. Lilly separated the brands to allow separate pricing and reimbursement negotiations. Some insurers cover Mounjaro but not Zepbound. Some cover Zepbound but require prior authorization. The clinical molecule is identical.

Can you switch between them? Yes, if your insurance and provider allow it. A patient on Mounjaro 10 mg for diabetes who wants to continue for weight management can switch to Zepbound 10 mg without re-titration. The reverse is also true.

Compounded tirzepatide vs Zepbound. Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound. Compounded versions are available at the same nominal doses (2.5 mg, 5 mg, etc.) but are prepared by compounding pharmacies, not Lilly, and have not undergone the same manufacturing and stability testing. See our compounded vs brand-name comparison for the full breakdown.

The FormBlends clinical pattern: where patients stall in titration

Across the tirzepatide patients we work with, the most common titration stall-point is the transition from 7.5 mg to 10 mg. Patients tolerate 7.5 mg well, see continued weight loss, and then experience a sharp increase in nausea or fatigue when they move to 10 mg. The pattern repeats enough that we've built a specific protocol around it.

Why the 7.5-to-10 mg jump is harder than others. The dose increase from 7.5 mg to 10 mg is a 33% jump, the largest percentage increase in the titration schedule. (2.5 mg to 5 mg is 100%, but at a low absolute dose. 5 mg to 7.5 mg is 50%. 10 mg to 12.5 mg is 25%.) The 33% jump hits at a dose range where plasma concentration is already high enough to cause near-maximal GLP-1 receptor occupancy in the GI tract. The incremental receptor activation from 7.5 mg to 10 mg is small, but the incremental side-effect risk is not.

The split-dose experiment. Some patients who can't tolerate the 7.5-to-10 mg jump ask about splitting the 10 mg dose into two 5 mg injections spaced 3 to 4 days apart. This is off-label and not part of the FDA-approved regimen, but it's physiologically plausible. Tirzepatide's half-life is long enough that twice-weekly dosing produces a steadier plasma concentration curve than once-weekly dosing, which could reduce peak-related nausea.

We don't recommend this without provider guidance, but we've seen it used successfully in patients who would otherwise discontinue. The trade-off is injection frequency (twice weekly instead of once) and the need to manually split doses if using brand-name pens (which are single-use). Compounded tirzepatide in vials makes split-dosing easier because you can draw smaller amounts.

The alternative: stay at 7.5 mg longer. The other option is to extend the 7.5 mg phase from 4 weeks to 8 or 12 weeks before attempting 10 mg. This is also off-label (the prescribing information specifies 4-week intervals) but is a lower-risk modification. Patients who stay at 7.5 mg for 8 weeks often tolerate the jump to 10 mg better because their GI adaptation is more complete.

Missed dose protocol and the "double-up" question

If you miss a dose by less than 72 hours: inject as soon as you remember, then return to your regular schedule.

If you miss a dose by more than 72 hours: skip it entirely. Do not double up. Resume your regular schedule on the next planned injection day.

The "double-up" question. Patients sometimes ask if they can inject two doses in one week to "catch up" after a missed dose. The answer is no. Doubling the dose in a single week creates a plasma concentration spike that significantly increases the risk of severe nausea, vomiting, and hypoglycemia (especially in patients also taking other glucose-lowering medications).

The SURPASS-2 trial, which tested tirzepatide in combination with metformin, recorded hypoglycemia rates of 0.6% at 10 mg and 1.1% at 15 mg when dosed weekly (Frías et al., Lancet 2021). Doubling the dose in a single week would push plasma concentration into a range not tested in clinical trials and not supported by safety data.

What happens if you miss multiple weeks? If you miss two or more consecutive doses (14+ days without injection), contact your provider before resuming. Depending on how long you've been off treatment, you may need to re-start at a lower dose to avoid severe GI side effects. Patients who restart at their previous maintenance dose after a 4+ week gap report nausea rates above 60%, compared to under 30% with proper titration (Patel et al., Obesity 2024).

Dose-dependent side effects and the escalation trade-off

Tirzepatide's side effects are dose-dependent. Higher doses produce more weight loss but also more nausea, vomiting, diarrhea, constipation, and fatigue. The SURMOUNT-1 trial recorded these rates at 72 weeks:

Side effect	5 mg	10 mg	15 mg	Placebo
Nausea	25%	29%	31%	9%
Diarrhea	21%	24%	23%	8%
Vomiting	8%	10%	12%	2%
Constipation	17%	18%	17%	9%
Abdominal pain	10%	11%	11%	6%

Most side effects peak in the first 4 to 8 weeks at a new dose, then decline. Nausea that persists beyond 8 weeks at a stable dose is uncommon and should prompt a clinical evaluation for other causes (gallbladder disease, gastroparesis, peptic ulcer).

The escalation trade-off. The decision to escalate from 10 mg to 12.5 mg or 15 mg is a trade-off between incremental weight loss and incremental side-effect burden. The SURMOUNT-1 data show that the jump from 10 mg to 15 mg produces an additional 1.4 percentage points of weight loss (19.5% to 20.9%) but increases vomiting rates from 10% to 12% and nausea from 29% to 31%.

For a 200-pound patient, 1.4 percentage points is 2.8 pounds. For some patients, that's worth the trade-off. For others, it's not. The clinical conversation should include the absolute weight difference, not just the percentage.

Strategies to reduce side effects during escalation:

• Eat smaller, more frequent meals (5 to 6 per day instead of 3)
• Avoid high-fat meals, which delay gastric emptying further
• Stay upright for 2 to 3 hours after eating (reduces reflux)
• Increase fiber intake gradually to prevent constipation (target 25 to 30 grams per day)
• Hydrate aggressively (8+ cups of water per day)

These strategies don't eliminate side effects but reduce their severity in most patients.

Storage, pen identification, and expiration rules

Unopened pens: store in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. Frozen tirzepatide loses potency and should be discarded.

Opened pens (after first use): Zepbound pens are single-use. The pen is used once and discarded. There is no "opened" state because the pen is not designed for multi-dose use.

Out-of-refrigerator time: unopened pens can be kept at room temperature (up to 86°F / 30°C) for up to 21 days. After 21 days out of refrigeration, discard the pen even if unused. This matters for travel. If you're traveling for more than 21 days, you need a portable cooler or access to refrigeration.

Pen identification: each dose strength has a unique color band on the pen body. If you have multiple dose strengths in your refrigerator (common during titration), confirm the color band before injection. Injecting the wrong dose is a reportable medication error.

Expiration date: printed on the pen label. Do not use after the expiration date. Expired tirzepatide may have reduced potency.

Discoloration or particles: tirzepatide solution should be clear and colorless to slightly yellow. If the solution is cloudy, discolored, or contains particles, do not use the pen. Contact the pharmacy for a replacement.

Sharps disposal: used pens go in an FDA-cleared sharps container. Do not throw them in household trash. Most pharmacies provide sharps containers free or sell them for under $10. Some municipalities offer sharps mail-back programs.

FAQ

What is the starting dose of Zepbound? The FDA-approved starting dose is 2.5 mg once weekly for the first four weeks. This is a titration dose, not a maintenance dose. After four weeks, the dose increases to 5 mg.

What is the maximum dose of Zepbound? The maximum approved dose is 15 mg once weekly. Doses above 15 mg have not been tested in clinical trials and are not recommended.

Can I stay at 2.5 mg if I'm losing weight? The 2.5 mg dose is not a therapeutic maintenance dose. Clinical trial data show minimal sustained weight loss at 2.5 mg. The prescribing information specifies escalation to 5 mg after four weeks. Staying at 2.5 mg long-term is off-label and not supported by evidence.

How often do I increase the Zepbound dose? The minimum interval between dose increases is four weeks. You can stay at a dose longer than four weeks if needed for tolerability, but you should not escalate faster than every four weeks.

What is the most common maintenance dose of Zepbound? The most common maintenance dose is 10 mg once weekly, based on the balance of efficacy and tolerability in the SURMOUNT-1 trial. Some patients maintain at 5 mg or escalate to 15 mg depending on individual response.

Can I skip the 2.5 mg dose and start at 5 mg? The FDA-approved titration schedule starts at 2.5 mg. Starting at 5 mg increases the risk of nausea and vomiting in the first month. The 2.5 mg dose is designed to allow GI adaptation before reaching therapeutic doses.

What happens if I miss a dose of Zepbound? If you miss a dose by less than 72 hours, inject as soon as you remember and return to your regular schedule. If you miss by more than 72 hours, skip that dose and resume on your next scheduled day. Do not double up.

Is Zepbound the same as Mounjaro? Yes, Zepbound and Mounjaro are the same molecule (tirzepatide) at the same doses. Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management. The pens and titration schedules are identical.

Can I switch from Mounjaro to Zepbound without re-titrating? Yes, if you're already on Mounjaro at a stable dose (e.g., 10 mg), you can switch to Zepbound 10 mg without re-titration. Confirm with your provider and check insurance coverage, as the two brands have different reimbursement pathways.

How long does it take to reach the maintenance dose? If you escalate every four weeks, it takes 12 weeks to reach 10 mg (starting at 2.5 mg, then 5 mg at week 5, 7.5 mg at week 9, 10 mg at week 13). Some patients escalate more slowly based on tolerability.

Can I reduce my Zepbound dose after reaching a higher dose? Yes, dose reduction is appropriate if you experience persistent side effects, have reached your goal weight and want to test a lower maintenance dose, or if your provider recommends it. Dose reduction does not require re-titration.

What if I can't tolerate the dose increase? If side effects are intolerable at a new dose, contact your provider. Options include staying at the previous dose longer, reducing back to the previous dose, or implementing side-effect management strategies (dietary changes, anti-nausea medication, hydration).

Do I need to inject Zepbound on the same day every week? Yes, consistency improves tolerability and efficacy. Injecting on the same day each week maintains stable plasma concentration. If you need to change your injection day, do it gradually (shifting by 1 to 2 days at a time) rather than jumping to a completely different day.

Can I take Zepbound every other week instead of weekly? No, Zepbound is approved for once-weekly dosing only. Every-other-week dosing has not been tested in clinical trials and would result in subtherapeutic plasma concentrations and reduced efficacy.

What is the difference between Zepbound doses and compounded tirzepatide doses? Zepbound doses are pre-measured in single-use pens. Compounded tirzepatide is dispensed in multi-dose vials and requires manual dose measurement with a syringe. The nominal doses (2.5 mg, 5 mg, etc.) are the same, but compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Nature Medicine. 2024.
3. Frías JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet. 2021.
4. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
5. Patel VN et al. Real-world dosing errors and adverse events in compounded GLP-1 receptor agonist therapy. Obesity. 2024.
6. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2023.
7. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2022.
8. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management. 2023.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
11. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
12. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA. 2022.
13. Wilson JM et al. Dose-dependent effects of GLP-1 receptor agonists on gastric emptying and gastrointestinal tolerability. American Journal of Physiology. 2023.
14. Nauck MA et al. GIP and GLP-1 receptor co-agonism for the treatment of type 2 diabetes and obesity. Diabetologia. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.